Time trends and survival of marginal zone lymphoma over 25 years in Girona, Spain (1994–2018)

To analyze the incidence, incidence trends, and survival of marginal zone lymphomas (MZLs) in Girona and to describe these indicators based on the location in the case of extranodal MZLs.

[1]  A. Rosenwald,et al.  The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms , 2022, Leukemia.

[2]  L. Thurner,et al.  Management of Extranodal Marginal Zone Lymphoma: Present and Upcoming Perspectives , 2022, Cancers.

[3]  J. Vaughn,et al.  Survival of patients with marginal zone lymphoma in the United States: A population‐based cohort study (2000 to 2017) , 2021, American journal of hematology.

[4]  D. Bishop,et al.  Risk factors for melanoma by anatomical site: an evaluation of aetiological heterogeneity * , 2020, The British journal of dermatology.

[5]  R. Marcos-Gragera,et al.  Population-based survival of lymphoid neoplasms: Twenty years of epidemiological data in the Girona province, Spain. , 2019, Cancer epidemiology.

[6]  Denisa Cuciureanu,et al.  MALT lymphoma: epidemiology, clinical diagnosis and treatment , 2018, Journal of medicine and life.

[7]  S. Swerdlow.  WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues , 2017 .

[8]  L. Lix,et al.  Long-term time trends in incidence, survival and mortality of lymphomas by subtype among adults in Manitoba, Canada: a population-based study using cancer registry data , 2017, BMJ Open.

[9]  C. Dearden,et al.  Epidemiology and environmental aspects of marginal zone lymphomas. , 2017, Best practice & research. Clinical haematology.

[10]  A. Polliack,et al.  Nodal marginal zone lymphoma: Clinical features, diagnosis, management and treatment. , 2017, Best practice & research. Clinical haematology.

[11]  R. Bruno,et al.  Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection. , 2016, Blood.

[12]  J. Cerhan,et al.  2016 US lymphoid malignancy statistics by World Health Organization subtypes , 2016, CA: a cancer journal for clinicians.

[13]  D. Rossi,et al.  Splenic marginal zone lymphoma: from genetics to management. , 2016, Blood.

[14]  F. Cavalli,et al.  Histologic transformation in marginal zone lymphomas†. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  H. Iguchi,et al.  Site-specific analysis of B-cell non-Hodgkin’s lymphomas of the head and neck: A retrospective 10-year observation , 2015, Acta oto-laryngologica.

[16]  T. Petrella,et al.  The heterogeneity of changes in incidence and survival among lymphoid malignancies in a 30-year French population-based registry , 2015, Leukemia & lymphoma.

[17]  Alexandra G. Smith,et al.  Lymphoma incidence, survival and prevalence 2004–2014: sub-type analyses from the UK's Haematological Malignancy Research Network , 2015, British Journal of Cancer.

[18]  M. Angelopoulou.  Transformed Nodal Marginal Zone Lymphoma versus Diffuse Large B Cell Lymphoma: The MicroRNA Aspect , 2014, Acta Haematologica.

[19]  G. Giles,et al.  Lymphoid neoplasm incidence by WHO subtype in Australia 1982–2006 , 2014, International journal of cancer.

[20]  G. Salles,et al.  Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment , 2014, Leukemia & lymphoma.

[21]  A. Salar,et al.  Simplification of risk stratification for splenic marginal zone lymphoma: a point-based score for practical use , 2014, Leukemia & lymphoma.

[22]  D. Weisenburger,et al.  Incidence of marginal zone lymphoma in the United States, 2001–2009 with a focus on primary anatomic site , 2014, British journal of haematology.

[23]  M. Hansmann,et al.  Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management. , 2013, Journal of hepatology.

[24]  N. Schmitz,et al.  ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  J. Castillo,et al.  Survival of patients with marginal zone lymphoma , 2013, Cancer.

[26]  Alexandra G. Smith,et al.  Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network , 2011, British Journal of Cancer.

[27]  R. Sankila,et al.  Survival of European patients diagnosed with lymphoid neoplasms in 2000–2002: results of the HAEMACARE project , 2011, Haematologica.

[28]  F. Berrino,et al.  Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. , 2010, Blood.

[29]  C. Copie-Bergman,et al.  Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  M. Federico,et al.  Decreasing incidence of gastric MALT lymphomas in the era of anti-Helicobacter pylori interventions: results from a population-based study on extranodal marginal zone lymphomas. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  R. Bende,et al.  Chronic inflammatory disease, lymphoid tissue neogenesis and extranodal marginal zone B-cell lymphomas , 2009, Haematologica.

[32]  J. Olsen,et al.  Autoimmune disease in individuals and close family members and susceptibility to non-Hodgkin's lymphoma. , 2008, Arthritis and rheumatism.

[33]  M. Federico,et al.  Incidence, clinical characteristics and survival of malignant lymphomas: a population‐based study from a cancer registry in northern Italy , 2007, Hematological oncology.

[34]  O. Hermine,et al.  Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. , 2006, Blood.

[35]  T. Akamatsu,et al.  Comparison of Localized Gastric Mucosa‐Associated Lymphoid Tissue (MALT) Lymphoma with and without Helicobacter pylori Infection , 2006, Helicobacter.

[36]  V. Moreno,et al.  Incidencia poblacional de las neoplasias linfoides según el subtipo histológico (Clasificación de la OMS) en Girona, 1994-2001 , 2006 .

[37]  H. Adami,et al.  Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. , 2006, Journal of the National Cancer Institute.

[38]  M. Dimopoulos,et al.  Non-Hodgkin’s Lymphomas in Greece according to the WHO Classification of Lymphoid Neoplasms , 2005, Acta Haematologica.

[39]  A. López-Guillermo,et al.  Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. , 2003, Blood.

[40]  X. Mariette,et al.  Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. , 2002, The New England journal of medicine.

[41]  G. Salles,et al.  Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. , 2000, Blood.

[42]  D. Verthelyi,et al.  Gender and risk of autoimmune diseases: possible role of estrogenic compounds. , 1999, Environmental health perspectives.

[43]  S J Gange,et al.  Epidemiology and estimated population burden of selected autoimmune diseases in the United States. , 1997, Clinical immunology and immunopathology.

[44]  P. Isaacson,et al.  Splenic Marginal Zone Cell Lymphoma , 1992, The American journal of surgical pathology.

[45]  P. Trott,et al.  International Classification of Diseases for Oncology , 1977 .

[46]  M. Sáez,et al.  Population-based incidence of lymphoid neoplasms: Twenty years of epidemiological data in the Girona province, Spain. , 2019, Cancer epidemiology.

[47]  Kaushik Kumar,et al.  Material Analysis for Blade of a Mixed Flow Pump Impeller Designed Through Mean Stream Line Method , 2017 .

[48]  D. Weisenburger,et al.  Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. , 2006, Blood.

[49]  S. Sanjosé,et al.  [Population-based incidence of lymphoid neoplasms by histological subtypes in Girona (Spain), 1994-2001]. , 2006, Medicina clínica (Ed. impresa).

[50]  M. Paulli,et al.  Marginal zone-related neoplasms of splenic and nodal origin. , 2003, Haematologica.